Evidence map›Paper›PMID 36145546›Full record

ArticlePharmaceutics2022

Quality by Design-Driven Zeta Potential Optimisation Study of Liposomes with Charge Imparting Membrane Additives.

Zsófia Németh, Ildikó Csóka, Reza Semnani Jazani, Bence Sipos, Henrik Haspel, Gábor Kozma, Zoltán Kónya, Dorina Gabriella Dobó

Abstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 147 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
147citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

147 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Nanoformulations in epilepsy therapy - a systematic review of emerging strategies in status epilepticus.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Design-ExpertPharmaceutics · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

87 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zsófia NémethFaculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, 6, Eötvös Street, H-6720 Szeged, Hungary.ORCID 0000-0003-3953-9831
Ildikó CsókaFaculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, 6, Eötvös Street, H-6720 Szeged, Hungary.ORCID 0000-0003-0807-2781
Reza Semnani JazaniFaculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, 6, Eötvös Street, H-6720 Szeged, Hungary.
Bence SiposFaculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, 6, Eötvös Street, H-6720 Szeged, Hungary.ORCID 0000-0002-0131-4728
Henrik HaspelDepartment of Applied and Environmental Chemistry, Faculty of Science and Informatics, Institute of Chemistry, University of Szeged, 1, Rerrich Béla Sqare, H-6720 Szeged, Hungary.ORCID 0000-0002-1362-2752
Gábor KozmaDepartment of Applied and Environmental Chemistry, Faculty of Science and Informatics, Institute of Chemistry, University of Szeged, 1, Rerrich Béla Sqare, H-6720 Szeged, Hungary.ORCID 0000-0003-2033-0720
Zoltán KónyaDepartment of Applied and Environmental Chemistry, Faculty of Science and Informatics, Institute of Chemistry, University of Szeged, 1, Rerrich Béla Sqare, H-6720 Szeged, Hungary.ORCID 0000-0002-9406-8596
Dorina Gabriella DobóFaculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, 6, Eötvös Street, H-6720 Szeged, Hungary.ORCID 0000-0001-9528-9983

Funding

Gedeon Richter Plc. Gedeon Richter's Talentum FoundationMinistry for Innovation and Technology TKP2021-EGA-32Ministry for Innovation and Technology ÚNKP-21-3-SZTE-271
6 · The paper itself

Abstract

Liposomal formulations, as versatile nanocarrier systems suitable for targeted delivery, have a highly focused role in the therapy development of unmet clinical needs and diagnostic imaging techniques. Formulating nanomedicine with suitable zeta potential is an essential but challenging task. Formulations with a minimum ±30 mV zeta potential are considered stable. The charge of the phospholipid bilayer can be adjusted with membrane additives. The present Quality by Design-derived study aimed to optimise liposomal formulations prepared via the thin-film hydration technique by applying stearylamine (SA) or dicetyl phosphate (DCP) as charge imparting agents. This 3

Indexed as

dicetyl phosphatefactorial designliposomeoptimisationstearylaminezeta potential

Identifiers

PMID36145546
PMCPMC9503861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.